Spero therapeutics financial statements

Author: qllo

August undefined, 2024

WebApr 13, 2024 · Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 13, 2024 CAMBRIDGE, Mass., … WebSpero Therapeutics Working Capitalis quite stable at the moment as compared to the past year. The company's current value of Working Capitalis estimated at 2.28 Million. Spero …

DEF14A - SEC

WebDec 31, 2024 · As of December 31, 2024, we had federal and state net operating loss carryforwards of $291.9 million and $282.9 million , respectively, which may be available to offset future income tax liabilities. The federal NOLs of $73.0 million will expire at various dates from 2033 to 2037 and approximately $218.9 million can be carried forward … WebSpero Therapeutics, Inc. income statement is the only one that provides an overview of company sales and net income The reasoning behind the adjustment, however, is that … biotene pbf dry mouth

Spero Therapeutics Inc (SPRO) Stock Price & News - Google

Web675 Massachusetts Avenue, 14 th Floor . Cambridge, Massachusetts 02139 . April 26, 2024 . To Our Stockholders: You are cordially invited to attend the 2024 annual meeting of stockholders of Spero Therapeutics, Inc. to be held at 9:00 a.m. Eastern Time on Wednesday, June 5, 2024 at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, … WebLegal Name Spero Therapeutics, Inc. Stock Symbol NASDAQ:SPRO. Company Type For Profit. Phone Number +1 857 242 1600. Spero Therapeutics is developing first in class … WebSpero Therapeutics financials statements overview reports - balance sheet, income statement, cash flow, earnings & estimates, ratio, and margins. View [DE:2HA] financial … biotene oral rinse vsmouthwash

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2024 Earnings Call …

SPERO THERAPEUTICS, INC. : Results of Operations and …

WebMay 4, 2024 · Spero shares soon peaked at about $22 apiece as the company began plans to seek regulatory approval. The FDA accepted its application on Jan. 3. However, almost all of Spero's market value has … WebSpero Therapeutics Working Capitalis quite stable at the moment as compared to the past year. The company's current value of Working Capitalis estimated at 2.28 Million. Spero Select Account or Indicator Net Income Per Employee Revenue Per Employee Average Assets Earnings Before Interest Taxes and Depreciation Amortization EBITDA dakina constructionsWebMar 31, 2024 · Spero reported net income of $26.8 million for the fourth quarter and a full year net loss of $46.4 million for the year ended December 31, 2024 or net income of … biotene oral spray how many times per day

"Web2 days ago · These research and poster presentations were sponsored by Spero Therapeutics, which was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Joint Warfighter Medical Research Program under Award No. W81XWH-19-1-0295.. About Spero Therapeutics Spero Therapeutics, headquartered in … " - Spero therapeutics financial statements

Spero therapeutics financial statements

SPRO Spero Therapeutics Inc. Financial Statements - WSJ

WebSpero Therapeutics Inc. Annual stock financials by MarketWatch. View the latest SPRO financial statements, income statements and financial ratios. WebApr 14, 2024 · Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.

Did you know?

WebApr 14, 2024 · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today … WebApr 13, 2024 · Shareholders in Spero Therapeutics, Inc. (NASDAQ:SPRO) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts have sharply increased their revenue numbers, with a view that Spero Therapeutics will make substantially more sales than ...

WebMay 3, 2024 · CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and... WebMar 10, 2024 · Get the detailed income statement for Spero Therapeutics, Inc. (SPRO). Up to 10 years of financial statements. Quarterly or annual. View as % YoY growth or as % of …

WebApr 10, 2024 · Spero Therapeutics, Inc. announced that it has received $8.999973 million in funding from GSK plc Nov 10 Spero Therapeutics to Present Data at IDWeek 2024 Oct 20 Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value Oct 03 See more updates Shareholder Returns See full shareholder … WebApr 10, 2024 · Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of . Spero …

WebSPRO Spero Therapeutics Inc. Annual Income Statement - WSJ Spero Therapeutics Inc. SPRO (U.S.: Nasdaq) View All companies AT CLOSE 4:00 PM EST 03/07/23 $1.69 USD …

WebApr 6, 2024 · April 5, 2024, 9:59 PM · 13 min read. Spero Therapeutics, Inc. (NASDAQ: SPRO) Q4 2024 Earnings Call Transcript March 30, 2024. Operator: Good afternoon, and welcome to Spero Therapeutics Fourth ... biotene pbf toothpasteWebMar 22, 2024 · Spero Therapeutics's market cap is currently ―. The company's EPS TTM is $-3.106; its P/E ratio is -0.45; Spero Therapeutics is scheduled to report earnings on … daki menan lands and resources corporationWebDec 31, 2024 · Item 2.02. Results of Operations and Financial Condition. On March 30, 2024, Spero Therapeutics, Inc. (the "Company") issued a press release announcing its results for the fourth quarter and full year ended December 31, 2024.A copy of the press release is furnished as Exhibit 99.1 hereto. The information contained in this Item 2.02 and in the … dakim brain fitness reviewsWebSpero Therapeutics, Inc Financial Statements – NASDAQ:SPRO – TradingView 1.40 USD +0.02 +1.45% Markets / US Stocks / Health Technology / Biotechnology / SPRO / … daki lost in the fireWebSep 29, 2024 · Item 1.01 Entry into a Material Definitive Agreement. On September 29, 2024, Spero Therapeutics, Inc. (the "Company") entered into a Revenue Interest Financing Agreement (the "Revenue Interest Agreement") with certain entities managed by Healthcare Royalty Management, LLC ("HCR"), pursuant to which the Company sold to HCR the right … biotene phone numberWebOn June 4, 2024, Spero Therapeutics, Inc. (the “Company”) updated its investor presentation (the “Investor Presentation”), which the Company expects to use in connection with general corporate presentations and will be made available on the Company’s website or distributed by the Company in hardcopy or electronic form. biotene pbf or rinse reviewsWebApr 14, 2024 · Spero Therapeutics’ ECCMID 2024 scientific exchange submissions can be found at Key Publications and Presentations on the Spero Therapeutics corporate website. These research and poster ... biotene over the counter